

Instructions for Authors 2018

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2018 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer. G. TOYOKAWA, K. TAKADA, T. TAGAWA, F. KINOSHITA, Y. KOZUMA, T. MATSUBARA, N. HARATAKE, S. TAKAMORI, T. AKAMINE, F. HIRAI, Y. YAMADA, R. HAMAMOTO, Y. ODA, Y. MAEHARA (<i>Fukuoka; Tokyo, Japan</i>)	3707
Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience. D. MANTAS, C. DAMASKOS, N. GARMPI, D. DIMITROULIS, A. GARMPI, H. GOGAS (<i>Athens, Greece</i>)	3713
Tumor Expression of <i>miR-10b</i> , <i>miR-21</i> , <i>miR-143</i> and <i>miR-145</i> Is Related to Clinicopathological Features of Gastric Cancer in a Central European Population. R. OBERMANNOVA, M. REDOVA-LOJOVA, P. VYCHYTILOVA-FALTEJSKOVA, P. GRELL, W.C. CHO, M. SACHLOVA, M. SVOBODA, R. VYZULA, O. SLABY (<i>Brno, Czech Republic; Hong Kong, PR China</i>)	3719
Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer. M. SIANO, N. JARISCH, M. JOERGER, V. ESPELI (<i>St. Gallen; Bellinzona, Switzerland</i>)	3725
Radiological Features of Brain Metastases from Non-small Cell Lung Cancer Harboring <i>EGFR</i> Mutation. S. TAKAMORI, G. TOYOKAWA, M. SHIMOKAWA, F. KINOSHITA, Y. KOZUMA, T. MATSUBARA, N. HARATAKE, T. AKAMINE, N. MUKAE, F. HIRAI, T. TAGAWA, Y. ODA, T. IWAKI, K. IIHARA, H. HONDA, Y. MAEHARA (<i>Fukuoka, Japan</i>).....	3731
Epidemiological Characteristics, <i>EGFR</i> Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. K.N. SYRIGOS, V. GEORGOULIAS, K. ZAROGOULIDIS, P. MAKRANTONAKIS, A. CHARPIDOU, C. CHRISTODOULOU (<i>Athens; Heraklion; Thessaloniki; Piraeus, Greece</i>)	3735
Clinical Relevance of Postoperative Neutrophil–Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer. H. TANAKA, T. TAMURA, T. TOYOKAWA, K. MUGURUMA, Y. MIKI, N. KUBO, K. SAKURAI, K. HIRAKAWA, M. OHIRA (<i>Osaka, Japan</i>)	3745
An Instrument for Estimating the 6-Month Survival Probability After Whole-brain Irradiation Alone for Cerebral Metastases from Gynecological Cancer. S. JANSSEN, H.C. HANSEN, S.E. SCHILD, D. RADES (<i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i>)	3753
Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges. J.Z. LAI, H.H. LAI, D. CAO (<i>St. Louis, MO, USA</i>)	3757
Vulvar Melanoma with Isolated Metastasis to the Extraocular Muscles: Case Report and Brief Literature Review. A.K. PIRLAMARLA, J. TANG, B. AMIN, R. KABARRITI (<i>Bronx, NY, USA</i>)	3763
Safety of Laparoscopic Surgery for Colorectal Cancer in Patients with Severe Comorbidities. S. SAWAZAKI, M. NUMATA, J. MORITA, Y. MAEZAWA, S. AMANO, T. AOYAMA, H. TAMAGAWA, T. SATO, T. OSHIMA, H. MUSHIAKE, N. YUKAWA, M. SHIOZAWA, Y. RINO, M. MASUDA (<i>Yokohama, Japan</i>)	3767
Postoperative Management of Multiple Primary Cancers Associated with Non-small Cell Lung Cancer. F. SHOJI, K. YAMAZAKI, N. MIURA, M. KATSURA, Y. OKU, S. TAKEO, Y. MAEHARA (<i>Fukuoka, Japan</i>)	3773
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients. H. TAKEOKA, K. YAMADA, Y. NAITO, N. MATSUO, H. ISHII, T. TOKITO, K. AZUMA, M. ICHIKI, T. HOSHINO (<i>Fukuoka; Kurume, Japan</i>)	3779
Retraction	3785

Oncologic Effectiveness and Safety of Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma: Meta-analysis of Randomized Controlled Trials. L. MARANO, F. RONDELLI, A. BARTOLI, M. TESTINI, G. CASTAGNOLI, G. CECCARELLI (<i>Spoletto; Perugia; Foligno; Bari, Italy</i>)	3609
The Role of PAR1 Autoantibodies in Patients with Primary Epithelial Ovarian Cancer. K. KREIENBRING, A. FRANZ, R. RICHTER, D. DRAGUN, H. HEIDECHE, D. MÜLLER, M. MENTZE, R. DECHEND, J. SEHOULI, E.I. BRAICU (<i>Berlin; Luckenwalde, Germany</i>)	3619
Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix – An Italian Multicenter Retrospective Study. A. GADDUCCI, F. LANDONI, S. COSIO, V. ZIZIOLI, P. ZOLA, A.M. FERRERO, M.T. LAPRESA, T. MAGGINO, E. SARTORI (<i>Pisa; Milan; Brescia; Turin; Mestre, Italy</i>)	3627
Is FDG-PET/CT Useful for Diagnosing Pulmonary Metastasis in Patients with Soft Tissue Sarcoma? T. HAGI, T. NAKAMURA, Y. SUGINO, T. MATSUBARA, K. ASANUMA, A. SUDO (<i>Tsu, Japan</i>)	3635
Fertility-sparing Surgery for Presumed Early-stage Invasive Cervical Cancer: A Survey of Practice in the United Kingdom. M. TZAFETAS, A. MITRA, I. KALLIALA, S. LEVER, C. FOTOPOULOU, A. FARTHING, J.R. SMITH, P. MARTIN-HIRSCH, E. PARASKEVAIDIS, M. KYRGIU (<i>London; Lancaster, UK; Helsinki, Finland; Ioannina, Greece</i>)	3641
Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases. V. TRESKA, O. TOPOLCAN, V. ZOUBKOVA, I. TRESKOVA, A. NARSANSKA, R. KUCERA (<i>Pilsen, Czech Republic</i>)	3647
Hyperfractionated or Accelerated Hyperfractionated Re-irradiation with ≥ 42 Gy in Combination with Paclitaxel for Secondary/Recurrent Head-and-Neck Cancer. D. RADES, T. BARTSCHT, C. IDEL, S.E. SCHILD, S.G. HAKIM (<i>Lübeck, Germany; Scottsdale, AZ, USA</i>)	3653
Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer. W. MALTER, M. HELLMICH, M. BADIAN, V. KIRN, P. MALLMANN, S. KRÄMER (<i>Cologne; Düsseldorf; Krefeld, Germany</i>)	3657
The Role of Interleukin-6 Polymorphism (rs1800795) in Prostate Cancer Development and Progression. J. JUREČEKOVÁ, H. DROBKOVÁ, M. ŠARLINOVÁ, E. BABUŠÍKOVÁ, M.K. SIVONOVÁ, T. MATÁKOVÁ, J. KLIMENT, E. HALAŠOVÁ (<i>Martin, Slovakia</i>)	3663
Malignant Transformation in Mature Cystic Teratomas of the Ovary: Case Reports and Review of the Literature. A. GADDUCCI, S. PISTOLESI, M.E. GUERRIERI, S. COSIO, F.G. CARBONE, A.G. NACCARATO (<i>Pisa, Italy</i>)	3669
Usefulness of Preoperative ^{18}F -FDG-PET in Detecting Invasive Intraductal Papillary Neoplasm of the Bile Duct. Y. IKENO, S. SEO, G. YAMAMOTO, Y. NAKAMOTO, Y. UEMOTO, H. FUJI, K. YOSHINO, T. YOH, K. TAURA, S. UEMOTO (<i>Kyoto; Shiga, Japan</i>)	3677
Co-occurrence of <i>MEN1</i> p.Gly111fs and <i>AIP</i> p.Arg16His Variants in Familial MEN1 Phenotype. F.M. DE MELO, L. BASTOS-RODRIGUES, M.M. SARQUIS, E. FRIEDMAN, L. DE MARCO (<i>Belo Horizonte, Brazil; Tel-Aviv, Israel</i>)	3683
Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. G.L. BANNA, A. CAMERINI, G. BRONTE, G. ANILE, A. ADDEO, F. RUNDO, G. ZANGHÌ, R. LAL, M. LIBRA (<i>Catania; Lido di Camaiore; Meldola; Padua, Italy; Geneva, Switzerland; London, UK</i>)	3689
Daily Setup Accuracy, Side-effects and Quality of Life During and After Prone Positioned Prostate Radiotherapy. L. VARGA, R.L. KÓSZÓ, E. FODOR, A. CSERHÁTI, Z. VARGA, B. DARÁZS, Z. KAHÁN, K. HIDEGHÉTY, E. BORZÁSI, D. SZABÓ, K. MÜLLNER, A. MARÁZ (<i>Szeged, Hungary</i>)	3699

Knockdown of 14-3-3 γ Suppresses Epithelial–Mesenchymal Transition and Reduces Metastatic Potential of Human Non-small Cell Lung Cancer Cells. P. RAUNGRUT, A. WONGKOTSILA, N. CHAMPOOCHANA, K. LIRDPRAPAMONGKOL, J. SVASTI, P. THONGSUKSAI (<i>Songkhla; Bangkok, Thailand</i>)	3507
Enigma Plays Roles in Survival of Thyroid Carcinoma Cells through PI3K/AKT Signaling and Survivin. Y.J. KIM, H.-J. HWANG, J.G. KANG, C.S. KIM, S.-H. IHM, M.G. CHOI, S.J. LEE (<i>Chuncheon, Republic of Korea</i>)	3515
Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells. N. KIM, M.-J. KANG, S.H. LEE, J.H. SON, J.E. LEE, W.H. PAIK, J.K. RYU, Y.-T. KIM (<i>Seoul; Goyang, Republic of Korea</i>).....	3527
<i>Clinical Studies</i>	
Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma. E. JUNG, M. FIORE, A. GRONCHI, V. GRIGNOL, R.E. POLLOCK, S.S. CHONG, S. CHOPRA, A.S. HAMILTON, W.W. TSENG (<i>Los Angeles, CA; Columbus, OH, USA; Milan, Italy</i>)	3535
Definitive Chemoradiation in Locally Advanced Squamous Cell Carcinoma of the Hypopharynx: Long-term Outcomes and Toxicity. A. JULOORI, S.A. KOYFMAN, J.L. GEIGER, N.P. JOSHI, N.M. WOODY, B.B. BURKEY, J. SCHARPF, E.L. LAMARRE, B. PRENDES, D.J. ADELSTEIN, J.F. GRESKOVICH, L. KELLER (<i>Cleveland, OH, USA</i>)	3543
Stromal p16 Overexpression in Gastric-type Mucinous Carcinoma of the Uterine Cervix. T. CHUNG, S.-I. DO, K. NA, G. KIM, Y.I. JEONG, Y.W. KIM, H.-S. KIM (<i>Seoul, Republic of Korea</i>).....	3551
Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. K. KOMIYA, C. NAKASHIMA, T. NAKAMURA, H. HIRAKAWA, T. ABE, S. OGUSU, K. TAKAHASHI, Y. TAKEDA, Y. EGASHIRA, S. KIMURA, N. SUEOKA-ARAGANE (<i>Saga, Japan</i>)	3559
Impact of Pleural Effusion on Outcomes of Patients Receiving Osimertinib for NSCLC Harboring <i>EGFR</i> T790M. K. MASUHIRO, T. SHIROYAMA, H. SUZUKI, S. TAKATA, S. NASU, H. TAKADA, S. MORITA, A. TANAKA, N. MORISHITA, N. OKAMOTO, T. HIRASHIMA (<i>Habikino, Japan</i>)	3567
Gallstone Patients with Enhanced Oxidative Stress Biomarker Superoxide Dismutase (SOD1) Plasma Levels Have Significantly Lower Number of Postoperative Analgesic Oxycodone Doses: A Prospective Study with Special Reference to Cancer Patients. J. KÄRKKÄINEN, I. SAIMANEN, T. SELANDER, S. ASPINEN, J. HARJU, P. JUVONEN, M. ESKELINEN (<i>Kuopio; Helsinki, Finland</i>)	3573
No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma. S. SHIBA, K. SHIBUYA, H. KATOH, Y. KOYAMA, M. OKAMOTO, T. ABE, T. OHNO, T. NAKANO (<i>Gunma, Japan</i>)	3579
Feasibility and Safety of CT-guided Intrathoracic and Bone Re-biopsy for Non-small Cell Lung Cancer. T. MATSUMOTO, T. HASEBE, Y. BABA, K. CHOSA, S. KONDO, S. YAMADA, R. YOSHIMATSU, T. KUBOTA, K. FUJITAKA, K. AWAI, T. YAMAGAMI (<i>Tokyo; Hiroshima; Kochi, Japan</i>)	3587
Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and \geq 75 Years. H. MIYAKE, R. AKI, Y. MATSUSHITA, K. TAMURA, D. MOTOYAMA, T. ITO, T. SUGIYAMA, A. OTSUKA (<i>Hamamatsu, Japan</i>)	3593
Altered Polyamine Profiles in Colorectal Cancer. M.K. VENÄLÄINEN, A.N. ROINE, M.R. HÄKKINEN, J.J. VEPSÄLÄINEN, P.S. KUMPULAINEN, M.S. KIVINIEMI, T. LEHTIMÄKI, N.K. OKSALA, T.K. RANTANEN (<i>Kuopio; Tampere; Seinäjoki, Finland</i>)	3601

Synthesis of Phosphoester Compounds Using Lactic Acid for Encapsulation of Paclitaxel. I. TAKEUCHI, R. MIKUNI, K. MAKINO (<i>Chiba, Japan</i>)	3401
Amyloid-beta Interactions with ABC Transporters and Resistance Modifiers. J. MOLNAR, I. OCSOVSZKI, R. PUSZTAI (<i>Szeged, Hungary</i>)	3407
Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma. K. ANDO, M. SAKODA, S. UENO, K. HIWATASHI, S. IINO, K. MINAMI, Y. KAWASAKI, M. HASHIGUCHI, K. TANOUE, Y. MATAKI, H. KURAHARA, K. MAEMURA, H. SHINCHI, S. NATSUGOE (<i>Kagoshima, Japan</i>)	3411
Mitofusin-2 Expression Is Implicated in Cervical Cancer Pathogenesis. S.Y. AHN, C. LI, X. ZHANG, Y.-M. HYUN (<i>Seoul, Republic of Korea; Yanji, PR China</i>)	3419
Silencing <i>Inc-ASAH2B-2</i> Inhibits Breast Cancer Cell Growth via the mTOR Pathway. J. LI, J. ZHANG, L. JIN, H. DENG, J. WU (<i>Guangzhou, PR China</i>)	3427
<i>In Vitro</i> and <i>In Vivo</i> Antitumor Effects of Pyrimethamine on Non-small Cell Lung Cancers. M.-X. LIN, S.-H. LIN, C.-C. LIN, C.-C. YANG, S.-Y. YUAN (<i>Taichung; Changhua; Tainan; Kaohsiung, Taiwan, ROC</i>)	3435
Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) via Endoscopic Microcatheter System. V. KHOSRAWIPOUR, A. MIKOLAJCZYK, J. SCHUBERT, T. KHOSRAWIPOUR (<i>Dortmund, Germany; Wroclaw, Poland; Irvine, CA, USA</i>)	3447
Differential Expression of IGF-I Transcripts in Bladder Cancer. N. MOURMOURAS, A. PHILIPPOU, P. CHRISTOPOULOS, K. KOSTOGLOU, C. GRIVAKI, C. KONSTANTINIDIS, E. SERAFETINIDES, D. DELAKAS, M. KOUTSILIERIS (<i>Athens, Greece</i>)	3453
Ampakines Attenuate Staurosporine-induced Cell Death in Primary Cortical Neurons: Implications in the 'Chemo-Brain' Phenomenon. D.P. RADIN, G.A. ROGERS, K.E. HEWITT, R. PURCELL, A. LIPPA (<i>Glen Rock, NJ, USA</i>)	3461
A Novel Modification of the AOM/DSS Model for Inducing Intestinal Adenomas in Mice. A. ANGELOU, N. ANDREATOS, E. ANTONIOU, A. ZACHARIOUDAKI, G. THEODOROPOULOS, C. DAMASKOS, N. GARMPIIS, C. YUAN, W. XIAO, S. THEOCHARIS, G. ZOGRAFOS, A. PAPALOIS, G.A. MARGONIS (<i>Athens; Pikermi, Greece; Baltimore, MD, USA; Beijing; Nanchang, PR China</i>)	3467
Sensitisation of Cancer Cells to MLN8237, an Aurora-A Inhibitor, by YAP/TAZ Inactivation. Y. OKU, N. NISHIYA, S. SUGIYAMA, H. SATO, Y. UEHARA (<i>Morioka, Japan</i>)	3471
MicroRNA-203 Induces Apoptosis by Targeting <i>Bmi-1</i> in YD-38 Oral Cancer Cells. J.-S. KIM, D.W. CHOI, C.S. KIM, S.-K. YU, H.-J. KIM, D.-S. GO, S.A. LEE, S.M. MOON, S.G. KIM, H.S. CHUN, J. KIM, J.-K. KIM, D.K. KIM (<i>Gwangju, Republic of Korea</i>)	3477
Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An <i>In Vitro</i> Study. L. TRIGGIANI, A. COLOSINI, M. BUGLIONE, N. PASINETTI, F. ORIZIO, L. BARDOSCIA, P. BORGHETTI, M. MADDALO, L. SPIAZZI, S.M. MAGRINI, R. BRESCIANI (<i>Brescia, Italy</i>)	3487
Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells. M. ISONO, A. SATO, T. ASANO, K. OKUBO, T. ASANO (<i>Tokorozawa, Japan</i>)	3493
Cystathionine Promotes the Proliferation of Human Astrocytoma U373 Cells. H. JURKOWSKA, M. WRÓBEL (<i>Krakow, Poland</i>)	3501

An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells. A. SAKAMOTO, K. KATO, T. HASEGAWA, S. IKEDA (<i>Tokyo; Saitama, Japan</i>)	3273
Quantitative Structure–Cytotoxicity Relationship of Furo[2,3- <i>b</i>]chromones. Y. UESAWA, H. SAKAGAMI, H. SHI, M. HIROSE, K. TAKAO, Y. SUGITA (<i>Tokyo; Saitama, Japan; Shanghai, PR China</i>)	3283
Combination Therapy with Glucan and Coenzyme Q ₁₀ in Murine Experimental Autoimmune Disease and Cancer. V. VETVICKA, J. VETVICKOVA (<i>Louisville, KY, USA</i>)	3291
Hapalindole H Induces Apoptosis as an Inhibitor of NF-κB and Affects the Intrinsic Mitochondrial Pathway in PC-3 Androgen-insensitive Prostate Cancer Cells. U. MUÑOZ ACUÑA, S. MO, J. ZI, J. ORJALA, E.J. CARCACHE DE BLANCO (<i>Columbus, OH; Chicago, IL, USA</i>)	3299
MiR-193a-5p and -3p Play a Distinct Role in Gastric Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by Targeting ETS1 and CCND1. N.-H. CHOU, Y.-H. LO, K.-C. WANG, C.-H. KANG, C.-Y. TSAI, K.-W. TSAI (<i>Kaohsiung; Pingtung, Taiwan, ROC</i>)	3309
mTOR Signalling Pathway-protein Expression in Post-transplant Cutaneous Squamous-cell Carcinomas Before and After Conversion to mTOR-inhibitors. T. KOLETSA, G. PETRAKIS, G. KARAYANNOPOULOU, S. EUVRARD, J. KANITAKIS (<i>Thessaloniki, Greece; Lyon, France</i>)	3319
SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1α. T. OKUNO, K. KAWAI, K. HATA, K. MURONO, S. EMOTO, M. KANEKO, K. SASAKI, T. NISHIKAWA, T. TANAKA, H. NOZAWA (<i>Tokyo, Japan</i>)	3323
Mycophenolate Mofetil Alone and in Combination with Tacrolimus Inhibits the Proliferation of HT-29 Human Colonic Adenocarcinoma Cell Line and Might Interfere with Colonic Tumorigenesis. G. LING, S. LAMPRECHT, G. SHUBINSKY, L. OSYNTSOV, B. YERUSHALMI, I. PINSK, V. PINSK, E. LING (<i>Beer Sheva; Ashdod, Israel</i>)	3333
Co-localisation of Glandular and Squamous Cell Markers in Non-small Cell Lung Cancer. H. KOYI, E. BRANDÉN, I. KASIM, E. WILANDER (<i>Stockholm; Gävle, Sweden</i>)	3341
ETS-1 Expression Is Hypoxia-independent in Glioblastoma-derived Endothelial and Mesenchymal Stem-like Cells. D. KOESSINGER, V. ALBRECHT, F. FABER, I. JAEHNERT, C. SCHICHOR (<i>Munich; Wuerzburg, Germany</i>)	3347
The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma. A. RUSAK, K. JABLONSKA, A. PIOTROWSKA, J. GRZEGRZOLKA, A. NOWAK, A. WOJNAR, P. DZIEGIEL (<i>Wroclaw, Poland</i>)	3357
Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer. T. ENKHBAT, M. NISHI, C. TAKASU, K. YOSHIKAWA, H. JUN, T. TOKUNAGA, H. KASHIHARA, D. ISHIKAWA, M. SHIMADA (<i>Tokushima, Japan</i>)	3367
Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven®): Combination with Anticancer Agents of Differing Mechanisms. M. ASANO, J. MATSUI, M.J. TOWLE, J. WU, S. MCGONIGLE, M.H. DE BOISFERON, T. UENAKA, K. NOMOTO, B.A. LITTLEFIELD (<i>Tsukuba, Japan; Andover, MA; Exton, PA; Woodcliff Lake, NJ, USA; Dijon, France</i>)	3375
The Impact of Indoleamine 2,3-dioxygenase (IDO) Expression on Stage III Gastric Cancer. M. NISHI, K. YOSHIKAWA, J. HIGASHIJIMA, T. TOKUNAGA, H. KASHIHARA, C. TAKASU, D. ISHIKAWA, Y. WADA, M. SHIMADA (<i>Tokushima, Japan</i>)	3387
Centrosome Clustering Is a Tumor-selective Target for the Improvement of Radiotherapy in Breast Cancer Cells. M.H. CHOE, J. KIM, J. AHN, S.-G. HWANG, J.S. OH, J.-S. KIM (<i>Seoul; Suwon; Daejeon, Republic of Korea</i>) ..	3393